The world's population is ageing. Today, 12 % of the world's population is 60 years of age and older, and by the middle of this century, this segment will rise to 22 %. [1] [2] [3] . This goes along with serious health concerns, as some of the most prevalent diseases are agerelated. More than 20 million people were estimated to have dementia in 2005 [4] . Today, dementia affects more than 40 million people worldwide [5] representing a significant burden for both patients as well as familial and institutional caregivers [6, 7] . By 2030, it is projected that more than 70 million people worldwide will suffer from dementia with further increasing prevalence, i.e. more than 130 million cases by 2050 [8] .
Alzheimer's disease (AD) is the most prevalent agerelated cause of dementia [9, 10] representing about 50 % to 70 % of the total cases [11, 12] . Because the primary risk factor for AD is age, the prevalence of the disease is increasing dramatically with the ageing populations worldwide [12, 13] .
Alzheimer's disease is a chronic neurodegenerative disorder characterized by progressive and irreversible cognitive decline [13, 14] . Clinically, AD is characterized by early memory deficits followed by a decline in cognitive functions [7, 12, 15] . Sporadic late-onset AD accounts for more than 99 % of all cases [16] , whereas early-onset AD is predominantly familial and caused by mutations in genes that encode amyloid precursor protein, presenilin 1 and presenilin 2 [7] .
It is well described that pathophysiological changes begin much earlier before clinical manifestations of the Abbreviations AD, Alzheimer's disease; ADRDA, AD and Related Disorders Association; APP, amyloid precursor protein; APTES, (3-Aminopropyl) triethoxysilane; Ab, amyloid b; CDT, clock drawing test; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; cryo-EM, cryoelectron microscopy; CSF, cerebrospinal fluid; EDC, N-Ethyl-N-(3-dimethylaminopropyl)carbodiimide; EGCG, epigallocatechin gallate; IVD, in vitro diagnostics; LTP, long-term potentiation; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NHS, N-Hydroxysuccinimide; NMR, nuclear magnetic resonance; PEG, polyethylene glycol; PET, positron emission tomography; PICUP, photo-induced crosslinking of unmodified proteins; sFIDA, surface-based fluorescence intensity distribution analysis. disease become overt [17, 18] . Major histopathological hallmarks of AD are neuronal atrophy, synaptic and neuronal loss mainly in the cerebral cortex and hippocampus, intraneuronal neurofibrillary tangles consisting of aggregated tau protein and the progressive accumulation of extracellular senile plaques composed of amyloid b (Ab) protein (Ab) [7, 9, 17, 19] . Furthermore, a synergistic interaction between the amyloid and tau pathology in AD is postulated, where neurotoxic Ab species modulate the activity of kinases and phosphatases inducing tau misfolding. Subsequent tau aggregation mediates synaptic dysfunction and neuronal death, which are the molecular signatures of underlying cognitive decline [20] [21] [22] . However, several lines of evidence indicate that not insoluble precipitation of larger aggregates such as senile plaques or intracellular neurofibrillary tangles rather than small soluble and highly neurotoxic Ab oligomers are the key drivers for AD pathogenesis [10, 18, 23, 24] .
Today, there are no preventive or curative options to treat Alzheimer's disease [13, 15, 25] . However, disease-modifying drugs are urgently needed to prevent, delay or treat the cognitive and behavioural symptoms of AD [26] . In the past two decades, more than 400 medication candidates failed to reach the clinical endpoints [27] , which has been mainly attributed to a lack of precise biomarkers for patient selection, therapy monitoring and measures of target engagement and outcome [7] . The discovery of a reliable biomarker of prodromal stages of AD, way before the onset of clinical manifestation, is one of the toughest challenges in AD research [19] , though would represent a major catalytic driver for the development of therapeutics and a fundamental prerequisite for its clinical application.
In this article, we review state-of-the-art knowledge on structural features of Ab oligomers and fibrils gained from solid-state nuclear magnetic resonance (NMR) spectroscopy and cryo-electron microscopy (cryo-EM) studies, and give an outline on innovations of an applied method for the quantitation of Ab oligomers from body fluids in the context of AD diagnostics. Furthermore, we draw conclusion from lessons we learned on assay optimization and provide an outlook on our path towards validation of a new in vitro diagnostic tool.
Main text

Structural features of amyloid b oligomers and aggregates
A detailed knowledge about the molecular structure of the misfolded Ab peptides involved in the aetiology of Alzheimer's disease is of paramount interest, not only in basic research but also for the development of therapeutic and diagnostic concepts. In the last two decades, a tremendous amount of effort has been put into the investigation of diverse oligomeric and fibrillar assemblies of Ab peptides of different length. Ab aggregates are noncrystalline and insoluble and therefore not accessible by the classical structure determination techniques solution NMR and X-ray crystallography. Recent methodological progress in the field of solidstate NMR spectroscopy and cryo-EM however has led to valuable insight into the structural organization of amyloid fibrils and oligomeric aggregates (for recent reviews see [28] [29] [30] [31] [32] [33] [34] ). Ab peptides are either 40 or 42 amino acid residues long, in addition, N-terminal truncation and pyroglutamate (pGlu) formation of residue E3 and E11 may occur, which affects structure and toxicity. Although Ab 1-42 is more neurotoxic than Ab 1-40 , pGlu 11 -Ab even exceeds the neurotoxicity of Ab 1-42 [35] . As a further consequence, Ab aggregates are heterogeneous and polymorphic [36, 37] , and even for amyloid fibrils grown from homogeneous monomer solutions in vitro the structure and supramolecular organization depends critically on the exact fibrillation conditions such as pH, ionic strength and stirring of the solution during fibril growth. Oligomeric aggregates and protofibrils are even more difficult to study, as these species form only transiently and with low abundance, and thus it is impossible to obtain monodisperse oligomer samples required for high-resolution structure determination. Nonetheless, substantial experimental insight into the structural organization on a variety of on and off pathways oligomers as well as protofilaments has been obtained in recent years. In the following paragraph, we will briefly review structural models of different Ab fibrils and oligomers.
Fibrils
Amyloid fibrils from wild-type Ab are the most extensively studied Ab assemblies, and early solid-state NMR spectroscopy studies from the group of Tycko have already demonstrated a strong tendency of Ab to form different polymorphic fibril types [38] . Solidstate NMR spectroscopy studies of the groups of Tycko, Bertini and Reif [39] [40] [41] characterized in total four different polymorphic fibril types which were obtained at slightly different fibrillation conditions in vitro. The morphology of the fibrils could also be transmitted by seeded fibril growth to subsequent samples. The common motif of the structural models derived from these studies is a cross-b structure consisting of parallel b-sheets with in-register arrangement of the monomers [39, 40] . In all models, the b-sheet core region was found in the C terminus starting from residue His13. The core region was postulated to form a U-shaped steric zipper motif consisting of two extended b-sheets connected by a turn region ranging from residues 24 to 30. Slight differences in the relative arrangement of the b-strands with respect to each other as well as in the supramolecular arrangement were found in different studies, and in all cases the fibril consisted of 2-3 protofilaments (Fig. 1A,B) . In all these studies, the N terminus was either completely disordered and flexible [39, 41] or at least structurally less well defined than the C terminus [40] . Finally, Tycko and coworkers used brain extracts from Alzheimer's disease patients with distinct clinical symptoms for seeded fibril growth of Ab in vitro and subsequent solid-state NMR characterization [42] [43] [44] . Seeded fibril growth with brain extracts from Alzheimer's disease patients distinctly altered the structure of Ab fibrils with respect to fibrils grown in vitro [42] , and seeding with brain extracts from different patients with distinct clinical subtypes resulted in fibrils with different morphology [43, 44] .
Early low-resolution cryo-EM studies of fibrils from Ab 1-40 by F€ andrich, Grigorieff and coworkers [37, 45, 46] confirmed the heterogeneous and polymorphic character of Ab 1-40 amyloid fibrils: 3D reconstructions from 12 individual fibrils from one single sample resulted in 12 different density maps with different cross-sections and twists. However, no atomic resolution details and thus no details about the location of the b-sheet core region could be obtained from these density maps. While one of the low-resolution density maps could be in agreement with the structural models proposed by Tycko and coworkers, most of the density maps showed pronounced differences.
A recent solid-state NMR study on Ab 1-40 fibrils from the early-onset mutant DE22, the so-called "Osaka mutant", resulted in an atomic resolution 3D structural model with a completely different structural organization: in this structural model, two molecules per layer are closely intertwined with each other, forming a cinnamon roll like fold. Additionally, in contrast to all structural models of Ab wild-type fibrils, the N terminus is also part of the core region (Fig. 1C) [47] . A recent comparison between solid-state NMR-spectra of N-terminally truncated and pyroglutamyl-modified pEAb and wild-type Ab did not reveal any differences in the core region, a finding which supports the hypothesis that in Ab fibrils the N terminus is not essential for fibril formation in fibrils from Ab [48] .
Ab is less abundant but more amyloidogenic and neurotoxic than Ab , and it has been demonstrated that Ab and Ab do not coaggregate but tend to form distinct homomolecular fibrils from a mixture of both peptides in vitro [49] . Three independent solidstate NMR studies of the groups of Ishii, Griffin and Meier/Riek have yielded atomic resolution structural models of Ab with virtually the same C-terminal Sshaped b-sheet core structure consisting of three parallel b-sheets with in-register alignment. This structural model decidedly differs from all structural models postulated for Ab [50] [51] [52] . Like for most fibrils from wild-type Ab the N terminus up to residue His14 was found to be disordered. The fibril consists of two protofilaments, where the interface between both subunits is defined by intermolecular hydrophobic contacts between the turn regions [51, 52] , and monomers in this model are connected by C2 symmetry, yielding a planar cross-section of the fibril (Fig. 1D,E) . Cryo-EM studies of Ab by Grigorieff and coworkers [53] as well as by Zhang et al. [54] yielded electron densities which are in agreement with a dimeric fibril subunit; however, these electron densities are not compatible with the structures determined by solid-state NMR spectroscopy. Finally, a recent combined cryo-EM and solid-state NMR study of Ab 1-42 fibrils grown at low pH resulted in a full 3D structure at high resolution [55] which has some similarities and also decided differences with respect to the solid-state NMR models: The C terminus forms an S-shaped fold which closely resembles that of the previous structures, however, in these fibrils the N terminus is rigid, well-ordered and part of the b-sheet core as well, with some similarities to the N terminus found in the structure of the Osaka mutant of Ab 1-40 [47] . The interface between the two protofilaments is formed mainly by hydrophobic contacts between the C termini and by an intermolecular salt bridge between Asp1 and Lys28. Furthermore, the protofilaments are twisted around each other and staggered against each other in such a way that the crosssection of the fibril is not planar, and each monomer is in contact with in total ten neighbouring monomers, five in each direction (Fig. 1F ).
Oligomers and protofibrils
For oligomeric and prefibrillar assemblies of different Ab peptides, the situation is even more complex, as the diverse Ab peptides are able to assemble into a variety of different oligomeric states which can be onpathway or off-pathway with respect to fibril formation; and due to their transient nature such prefibrillar assemblies are structurally heterogeneous and their concentration is limited. Thus, no unique widely accepted structural model for Ab oligomers exists so far. Nevertheless, as oligomers are supposed to be the pathologically relevant species in neurotoxicity of AD, structural information on these oligomeric species is of paramount interest, and in the last decade, different attempts have been made to stabilize oligomeric intermediates for further structural characterization: stable preparations of oligomers have been obtained either by freeze trapping the solution after different incubation times with or without subsequent lyophilization [56] [57] , by applying special incubation conditions such as low temperature and low salt concentration [58] or incubation in the presence of detergents [59, 60] , by addition of epigallocatechin gallate (EGCG) [61] or protofilaments stabilizing antibodies [62, 63] or even by engineered mutagenesis of the Ab peptide [64, 65] . Although such oligomer preparations were not homogeneous enough for high-resolution structure determination, size and shape of these oligomers could be determined by AFM and/or EM, and secondary structure information as well as information about supramolecular arrangement were obtained by solidstate NMR spectroscopy. However, details on the preparation and stabilization of the in vitro generated oligomers have a strong influence on the structural details. One consensus of these studies is that the secondary structure of Ab molecules in oligomeric preparations are similar to those in fibrils, but the supramolecular arrangement may be different. While virtually all structural models of mature Ab fibrils agree on an in-register parallel intermolecular alignment of b-sheets, for oligomeric species, the supramolecular arrangement as well as the b-sheet alignment strongly depends on the stage of fibril formation (Fig. 2) .
In 2008, Hoyer et al. [66] stabilized monomeric Ab 1-40 with an engineered b-binding protein and determined the structure of this complex by solution NMR spectroscopy. The monomer formed an intramolecular b-hairpin with two antiparallel b-strands which roughly resemble the b-strands in mature fibrils, a finding which led to the hypothesis that the transition from early oligomers to mature fibrils may be characterized by a switch from antiparallel intramolecular to parallel intermolecular b-sheets. Stabilization of this antiparallel b-sheet by a disulphide bond between position 21 and 30 in double Ala to Cys mutants of Ab and Ab indeed could stabilize toxic oligomers and prevent fibril formation [64] . Oligomers from such Ab 42 cc molecules were characterized by solid-state NMR spectroscopy and AFM, resulting in a structural model which consists of a hexameric b-barrel formed by six antiparallel intramolecular b-hairpins (Fig. 2C) . The hydrophobic core region involving the C-terminal amino acid residues 34-42 was found to form short intermolecular b-sheets [65] . A study by the group of Huster on antibody stabilized protofibrils of Ab 1-40 also supports the hypothesis of a b-sheet remodelling from intramolecular antiparallel to parallel intermolecular upon maturation [62, 63] . For the Iowa mutant D23N-Ab 1-40 , protofilaments with antiparallel b-sheets could be prepared selectively by repeated seeding [67, 68] . However, those fibrils are thermodynamically metastable and evolve towards purely parallel structures by gradual dissolution and growth [68] . Time resolved oligomer and fibril formation was monitored by Tycko and coworkers: frozen solutions of Ab 1-40 after different incubation times were investigated by DNP-enhanced solid-state NMR spectroscopy, and thus, four successive stages of Ab starting from monomeric solution to mature amyloid fibrils could be characterized [57] . The conformational order was found to increase continuously upon fibrillation, and secondary structure as well as one significant interside-chain contact could already be observed in the early oligomeric stages. However, parallel in-register b-sheets could in this case be observed only for mature fibrils and not for oligomers.
Toxicity of low molecular Ab assemblies
The most widely accepted hypothesis to explain the pathogenesis of Alzheimer's disease (AD) is the amyloid cascade, formalized by Hardy and Higgins [69] , which states that b-sheeted Ab proteins aggregate and deposit as extracellular plaques generated by the proteolytic cleavage of the amyloid precursor protein (APP) and intracellular tangles as central drivers of disease progression [10, 70, 71] . Early-onset AD induced by Ab mutations provide a strong link between pathogenesis and protein aggregation [32] .
However, mounting evidence suggests that soluble, oligomeric Ab assemblies cause substantial neuronal dysfunction before the appearance of amyloid deposits [72, 73] . It has been found that the total quantity of fibrillar Ab load in brain tissue does not directly correlate with the progression of clinical symptoms [57, 73, 74] , as indicated by studies of human brain extracts [75] and transgenic mice, where decreased density of presynaptic terminals and neurons preceded amyloid deposition, suggesting a neurotoxic effect of Ab that is independent of plaque formation [76] . Biochemical features of AD include altered calcium, phospholipid, and cholesterol metabolism as well as perturbed mitochondrial dynamics and function that also often appear early in the course of the disease, prior to plaque and tangle accumulation [70] . Mature amyloid fibril formation and deposition thus may be rather inert end stages of a molecular cascade of processes in which the pathogenic events occur much earlier and are mediated by neurotoxic oligomeric assemblies [74, [77] [78] [79] [80] .
In 2002, Kirkitadze et al. [77] declared this as a paradigm shift in understanding neurodegeneration in AD with soluble, oligomeric forms of Ab as the potent neurotoxic agent, and the proximate effectors of the neuronal injury and death occurring in AD. Recent attention has focused on early protein assemblies or intermediates of aggregation referred to as 'protofibrils', 'annular protofibrils', 'soluble oligomers' or 'globular neurotoxins' [79] [80] [81] [82] .
The minimal size of such oligomers is under debate. Although recent reports have shown that Ab monomers are not toxic, some studies claim that Ab dimers are existing and are three times more toxic than monomers and that Ab tetramers were 13 times more toxic than monomers, whatever this may tell us on the highly various assay conditions that have been used to come to the respective conclusions. Likewise nonamers and dodecamers have been described to be associated with deleterious effects on cognition [72, 79, 83] . However, these findings support the concept of the high toxicity of low molecular weight Ab oligomers. A recent study has shown that during Ab aggregation the smallest populated assemblies consist of five or six Ab units [84] suggesting that this is the minimal size for seed formation.
In fact, biochemical studies have demonstrated a good correlation between the levels of soluble Ab oligomers in the brains of patients with AD and the degree of cognitive impairment [19] . Furthermore, it has been shown in numerous studies that Ab oligomers induce disruption of membrane integrity [72] , tau hyperphosphorylation [85] , oxidative stress [86] , proteasome inhibition [87] , mitochondrial perturbation [88] , dysregulation of calcium homeostasis [89, 90] , synaptic failure and cognitive dysfunction [71, 78] .
The complex molecular mechanism of neuronal cell death induced by Ab oligomers resulting in neurodegeneration is a major subject of research. Vargas et al. (2014) [91] showed that Ab oligomers bind to synaptic regions leading to EphA4 receptor activation and to downstream phosphorylation (activation) of c-Abl which in turn triggers downstream effector signalling events that drive actin cytoskeleton rearrangements, promoting spine loss and causing cell death in more advanced disease stages. In Ab oligomer-treated animals, COX-2, IL-1b and TNFa proteins are expressed in reactive astrocytes surrounding the injection site and blood vessels at early stages of Ab toxicity. Double-labelling immunofluorescence studies also revealed that GFAP and COX-2 proteins colocalize with NF-jB-positive material at early points in time [92] . Furthermore, it has been reported that Ab oligomers reduce the amplitude of synaptic response in primary rat embryonic hippocampal neuron cultures [93] , and that cerebral microinjection of cell medium containing Ab oligomers potently inhibits hippocampal long-term potentiation in rats in vivo [94] .
Strittmatter and colleagues could show that cellular prion protein (PrP C ) is a functional receptor with high affinity for Ab oligomers inducing downstream signalling, which affects long-term potentiation (LTP) and synaptic plasticity [95] . By expression cloning studies in COS-7 cells, Nygaard and Strittmatter (2009) identified PrP C as a high-affinity binding site for Ab oligomers [95] . Specific interaction of Ab oligomers and PrP C was observed in human COS cells and in primary neurons [96] . Gunther et al. (2010) showed that Ab oligomers suppress LTP in mouse hippocampal brain slices in vitro, which was confirmed by other groups as summarized by Nygaard et al. [95] . Strikingly, this suppression was PrP C dependent as shown in genetically PrP C -deficient brain slices from mice or in the presence of an anti-PrP antibody that inhibits binding of Ab oligomers to PrP C [97] suggesting a critical role of PrP C in Ab oligomer-induced synaptotoxicity [97] . A tight linkage of PrP C and Ab oligomer interaction with cognitive decline and other AD features such as synaptotoxicity and decreased survival in mice was shown in multiple AD mouse models as reviewed by Kostylev et al. [98] . Of note, the authors emphasize the variation of different Ab-oligomer/PrP C fractions and the putative distinct relevance of different Ab oligomer species for molecular mechanisms towards AD pathology [98] of which the activation of Fyn kinase is a central player in signal transduction. Fyn, a member of the Src kinase family, plays a crucial role in mediating Ab-oligomer/PrP C dependent signalling at the postsynaptic density in neurons and AD phenotype expression as seen in different mouse models [96, [99] [100] [101] . Fyn inhibition rescues memory and synapse loss in AD mice [101] . Um and colleagues showed that Ab oligomers induce PrP C -dependent Fyn activation [102] . Larson et al. [100] affirmed this finding and identified implications to tau pathology. Fyn associates with tau and phosphorylates tyrosine residues near the amino terminus. Ab-oligomer/PrP Cdependent activation of Fyn induces tau hyperphosphorylation in primary mouse neurons.
Furthermore, Ab oligomers induce on the one hand PrP C /Fyn-dependent phosphorylation of the NR2B subunit of NMDA receptors, which results in a loss of surface NMDA receptors [99] . On the other hand, PrP C and mGluR5 function as a complex to mediate Ab oligomer induced signalling [103] . Ab oligomers inhibit glutamate induced activation of the PrP C / mGluR5 complex [96, 104] . Fyn-dependent mGluR5 and NMDA receptor inhibition provides an important proximal link for Ab oligomer-induced synaptic impairment.
Need for early-stage diagnostics of Alzheimer's disease
Development and application of treatments for AD rely on an unequivocal and early diagnosis. A reliable and early diagnosis could enhance development of therapeutic drugs and would be a prerequisite for its application in the clinical routine.
Among individuals living with AD and other dementias, diagnostic coverage is low. In most highincome countries, only 40 % to 50 % of people living with dementia receive a diagnosis. In low-income countries, there are few available estimates but diagnostic coverage is unlikely to exceed 5 % to 10 % [8] .
In 1984, first criteria from the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the AD and Related Disorders Association (ADRDA) were developed for the diagnosis of AD [105] . According to the former NINCDS/ ADRDA criteria, Alzheimer's disease could be definitely diagnosed only postmortem with a sensitivity of 91-98 %, however, with a very poor specificity of 40-61 % [106, 107] .
Current approaches which seek to improve AD diagnostic by biological measures beyond neuropsychological testing include cerebrospinal fluid (CSF) biochemical analyses (Ab 1-42 , total-tau, phospho T181 -tau) [108] [109] [110] , positron emission tomography (amyloid PET, fluordesoxyglucose PET, tau PET) and magnetic resonance imaging (fMRI, vMRI) [17, 105, 111, 112] .
The screening and identification of subjects in the preclinical or early clinical stages of AD is an important issue for early and more accurate diagnosis, prediction of disease progression, identification of potentially benefiting candidates for therapies in drug trials and to assess the progression of the disease. This implies diligent considerations on significant aspects of biomarker development such as (non)invasivity, time and cost effectivity and accessibility [107, 113, 114] . Furthermore, translation of biomarker research into clinical practice follows sufficient evidence of analytical validity, clinical validity and clinical utility of biomarkers and the respective in vitro diagnostic assays [105] , which requires first and foremost preceding validation on essential assay parameters such as robustness, precision, trueness, uncertainty, limits of quantification, dilutional linearity, parallelism, recovery, selectivity and sample stability [115] . Major characteristics of an ideal biomarkers are a sensitivity of at least 80 %, a specificity of at least 80 %, a positive predictive value close to 90 %, early disease detection, reliability, no or minimal invasiveness, low costs, involvement or representation of the pathophysiology and discrimination from other diseases [19] .
Admittedly, the use of preclinical diagnostic biomarkers in the absence of a treatment that delays disease progression questions its legitimacy from an ethical point of view. Although the onset of AD cannot yet be stopped or reversed, an early diagnosis offers already today benefits to help affected individuals and their families providing the chance to plan for the future by making financial and legal arrangements and address safety, care and living issues [116, 117] .
Current efforts in the development of early-stage diagnostics
So far, there is no unique method available to predict, determine or exclude the onset of AD. The process of making an AD diagnosis is rather a long road comprising anamnesis, physical examinations, psychometric tests, blood and CSF testing, as well as brain imaging techniques.
At the beginning of each diagnosis, a detailed anamnesis and physical examinations are indispensable on the one hand to prepare the way for follow-up examinations and on the other hand for differential diagnosis. AD symptoms, especially early in the course of disease, are often overlapping with other neurological disorders, such as Morbus Parkinson, frontotemporal dementia multiple sclerosis and mental illnesses such as depression and schizophrenia. In addition, blood tests are carried out, which provide further important information on the cause of the complaints. Inflammatory processes, infections, blood disorders, liver, kidney and thyroid diseases as well as diabetes can affect cognitive capability beyond AD.
Currently, AD is diagnosed by neurological examinations using psychometric tests, such as the Mini-Mental State Examination (MMSE) [118] , the Structured Interview for the Diagnosis of Dementia of the Alzheimer Type, Multi-infarct Dementia and Dementia of other Aetiology (SIDAM) [119] , test batteries according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) [120] , the Demenz-Detection-Test (DemTect) [121, 122] and the clock drawing test (CDT) [123, 124] based on the patients memory and cognition as well as visuospatial orientation.
Over the past decade, in vivo brain imaging by positron emission tomography (PET) evolved as a promising tool for the early detection of AD through visualization of abnormalities in brain structure, function, histopathology, deposits and neuronal activity with the discovery of Ab and glucose PET tracers respectively [125] . Several studies have shown that cerebral metabolic alterations precede the clinical manifestation of AD symptoms. Distinct patterns of cerebral glucose metabolism also help in differentiating AD from other causes of dementia [126, 127] . Since the development of the first Ab radioligand 11 C-benzothiazole, Pittsburgh compound B (PiB) [128] , the US Food and Drug Administration (FDA) has approved three agents for imaging Ab in the setting of AD, i.e. florbetapir [129, 130] (2012), flutemetamol [131] (2013) and florbetaben [132, 133] (2014). Although amyloid PET has demonstrated analytical value, its clinical utility is under debate. PET is expensive, requires extensive operator and analysis training, and is not widely available, which limits its wider clinical adoption, especially for very early disease [134, 135] .
Besides Ab tracers for PET, several approaches point to potential biochemical biomarkers, such as [137] . The authors found an increase in CSF tau and a decrease in CSF Ab 1-42 levels in AD, in agreement with results of several other reported follow-up studies [138] [139] [140] [141] . The combination of phosphorylated tau and Ab 1-42 levels as a diagnostic biomarker yielded approximately 85 % sensitivity and specificity for AD.
Lewczuk et al. [142] confirmed that decreased concentrations of Ab in CSF correlate with the progression of AD. Furthermore, the authors demonstrated that normalization of Ab concentration to the level of total Ab or Ab in CSF improves the accuracy of clinical AD diagnosis by controlling for interindividual differences in overall levels of Ab in CSF [142] .
This finding is consistent with Hansson et al. [143] who found that Ab concentration in CSF at baseline and the Ab 1-42 /Ab 1-40 ratio were significantly decreased in patients with mild cognitive impairment (MCI) that developed AD as compared to cognitively stable MCI patients and MCI patients who developed other forms of dementia. In conclusion, the data provide further support for the usefulness of the Ab 1-42 /Ab 1-40 ratio as a predictive biomarker for AD.
Englund et al. [144] found evidence that the lowering of monomeric Ab 1-42 might be caused by its oligomerization and deposition in plaques, thus leading to masking of the epitopes for the antibodies used in ligand-based analytical methods [145] . Wang-Dietrich et al. [146] underlines this hypothesis by results from an sFIDA assay, where in contrast the number of detected Ab oligomers is elevated after clinical onset of AD. These findings suggest that Ab oligomers, besides being the central neurotoxic agent, are potentially the most direct biomarker for AD. Of particular interest are indications that Ab oligomer assays may detect individuals with MCI who have a high risk of developing AD. But first of all, assay qualification in the field of oligomer-based techniques has to overcome tough challenges that are (a) the analytical discrimination of monomers and oligomers, (b) the low abundance of Ab oligomers by comparison to an excessive concentration of monomers, as well as (c) the interaction of Ab oligomers with matrix components. Recent developments evolved which lined up to overcome these challenges. Among these, ELISA-based techniques and variants thereof are the largest class. Variants include the application of proprietary Ab oligomer specific antibodies or the application of the same antibody for both antigen immobilization and detection of oligomers, thus rendering the assay on the one hand insensitive towards Ab monomers and on the other hand exclusively sensitive for Ab oligomers.
H€ oltt€ a et al. (2012) developed a sandwich ELISA using the same N-terminally specific Ab antibody as both capture and detection antibody to measure Ab oligomers in CSF. The authors demonstrated that antibodies specific to the N terminus of Ab have a higher affinity against fibrillar Ab oligomers than antibodies with an epitope against the more C-terminal part of the Ab sequence [147, 148] , indicating that the N-terminal part of the Ab sequence is the most likely one to be exposed in Ab aggregates. By this approach, AD patients could be consistently discriminated from controls [149] . Savage et al. (2014) established an Ab oligomer ELISA based on an oligomer-selective human antibody and with this demonstrated a significant 3-5 fold increase in Ab oligomers in human AD CSF compared with controls. With 80 % sensitivity and 88 % specificity to detect AD, the authors suggest a reasonable discriminatory power for the AD state and the potential for utility as a diagnostic marker [150] .
In 2015, Yang et al. reported achieving a similar degree of sensitivity and specificity with their sandwich immunoassay, but the signals in two cohorts of AD and age-matched control CSF samples overlapped substantially, while MCI subjects showed a trend towards having slightly higher levels of Ab oligomers compared to control subjects [151, 152] .
sFIDA: principle and unique features
Basic concept
The sFIDA (surface-based fluorescence intensity distribution analysis) assay is an oligomer-specific quantitation platform for counting single proteinaceous particles such as Ab oligomers from cerebrospinal fluid in the context of AD. The sFIDA technology combines an ELISA-like biochemical setup with highresolution fluorescence microscopy.
In sFIDA (Fig. 3) , Ab species are captured on a functionalized glass surface by an anti-Ab antibody directed against the N terminus. The captured oligomers and aggregates are decorated by two different fluorescent-labelling antibodies. Since the same or overlapping epitopes are recognized by both capture and detection antibodies, fluorescent-labelling of capture-bound Ab monomers is avoided thus rendering the assay insensitive for monomeric Ab. The use of two different anti-Ab antibodies, each one labelled with another fluorescent dye, further increases the specificity of the assay.
The assay surface is scanned by high-resolution fluorescence microscopy. The number of colocalized pixels in both fluorescence channels is referred to as sFIDA readout and directly correlates with the concentration of Ab oligomers in the sample. By applying calibration standards, the sFIDA readout is translated into molar concentration, thus ensuring absolute quantitation, interassay reproducibility and validity. The implementation of a fully automated liquid handling system initiates the translation of the method from applied research to routine diagnostics.
Biochemical setup and imaging
The biochemical setup of the sFIDA method consists of a thin glass surface that is coated with a bio-repellent layer, such as polyethylene glycol to which capture antibodies can be covalently bound. The capture antibodies are capable to enrich Ab agents from a complex matrix and allow removing excessive components by washing. Finally, immobilized Ab oligomers are decorated specifically by monoclonal antibodies that are tagged with fluorescent chromophores.
As a prerequisite for the coupling of the borosilicate waver surface to PEG as a spacer between the biological sample and the glass surface the glass bottom is functionalized by (3-Aminopropyl) triethoxysilane (APTES). Monolayers of APTES are prepared by exposing the glass waver to a vaporizing solution of APTES in dry toluene in a ratio of 1 : 20 (v/v) under argon for 1 h.
Proper control of reaction conditions is important to achieve the desired results in the amination of silica by APTES as essential reaction condition parameters, such as temperature, solution concentration, and reaction time affect structure and morphology of APTES coverage. Differences in the basic surface morphology, such as smoothness and thickness of the film, affect wettability and the extent of hydrolysation for thin films of APTES on silica [153] . Furthermore, hydrolysis of silane drives the attachment of the APTES to the substrate resulting in siloxane bonds at the substrate surface [153] . Other suitable methods to create an acceptable number of amino grafting sites for polyethylene glycol attachment include functionalization with other amines, such as ethanolamine [154] and aminophenyl-trimethoxysilane [155] .
After the chemisorption of 3-aminopropyl-triethoxysilane on a glass surface, the terminal amino groups condense with polyethylene glycol to introduce on the one hand a spacer between the surface and subsequent layers of antibody to avoid unspecific binding of matrix components and antibodies to the glass surface and thus minimizing the background signal. The polyethylene glycol layer represents a linker for a robust covalent bond of capture antibodies on the surface. For this purpose, a heterobifunctional polyethylene glycol, comprising an NHS ester at one terminal and a carboxylic function at the opposing end is used in water at a concentration of 2 mM and incubated for 4 h. An amide bond is formed between the primary amine on the surface and the activated ester of polyethylene glycol. Other suitable spacer methods to shield the assay surface from unspecific binders include carboxylic acid functionalized polysaccharides, such as carboxymethyldextran, in combination with watersoluble catalysts such as carbodiimides.
An anti-Ab antibody is covalently linked to the polyethylene glycol-treated surface as a capture for Ab species eventually contained in the samples. For this reaction, carboxylic acids on surface bound polyethylene glycol are activated by 200 mM N-Ethyl-N-(3-dimethylaminopropyl)carbodiimide (EDC) and 50 mM N-Hydroxysuccinimide (NHS). This reaction transforms the terminal carboxylic acids to amine reactive NHS esters. The capture antibody is added after the excessive reagents are removed and incubated for 1 h at room temperature for covalent immobilization to the polyethylene glycol layer. To deactivate remaining carboxylate end groups of the polyethylene glycol spacer the surface is washed with TRIS (tris(hydroxymethyl)aminomethane) buffer.
After incubation of the samples and thorough washing, fluorescent-labelled anti-Ab antibodies are applied to decorate Ab oligomers in the sample followed by consecutive washing steps to remove unspecifically bound detection probes.
Using total internal reflection (TIRF) microscopy, the glass surface is scanned [156] and pixels with intensity values above given cutoffs and at exactly the same position in both channels are counted for each image and considered as colocalized, where the number of colocalized pixels is referred to as "sFIDA readout" [146] . Based on the application of a suitable calibration standard of known concentration and linear regression, the concentration of Ab oligomers in the sample is calculated from the sFIDA readout.
Proof of principle
In a proof of principle study, Wang-Dietrich et al. determined the Ab oligomer content by means of sFIDA of CSF samples from 14 AD patients and 12 age-matched controls which revealed a clear distinction between both groups. All samples of the control group showed consistently low numbers of Ab oligomers, while the samples of the AD group exhibited significantly higher levels of Ab oligomers. The Ab oligomer numbers correlated with the patients' Mini-Mental State Examination scores. This indicates that the quantity of Ab oligomers in CSF reflects the severity of the disease and that Ab oligomers play a crucial role in AD pathology and in turn can be used as a diagnostic biomarker [146] .
Since then, the sFIDA method underwent fundamental optimization in respect to automation [157] , adaptation to blood-based analysis [158] and development of a suitable calibration standards [159] .
Calibration standards
Standards are a crucial component of any immunoassay, necessary to assess the assay's validity, serve as calibrator to determine the quantity of the analyte and allow the comparison of results with other assays. In method development, standards are the starting point for optimization processes and investigations of matrix interferences. Ideally, the standard is identical to the analyte, well characterized, highly pure, stable, and has a precisely determined concentration. If the analyte is an aggregated species, such as Ab oligomers, the corresponding standard needs to be prepared by precise methods and analysed just before each assay. However, such time-consuming preparations are often also instable due to dynamic aggregation and dissociation of the oligomers [160] and can therefore cause variations among and within laboratories [161] .
To overcome this limitation, stable oligomeric standards have been developed, which use photo-induced cross-linking of unmodified proteins (PICUP) to form covalent bonds between monomers [64, [162] [163] [164] . In this method the protein monomers are aggregated and form oligomeric species in a broad size range, which are then separated by size exclusion chromatography. The fractions are then irradiated by UV light in the presence of Ru(Bpy) (Tris(2,2 0 -bipyridyl)dichlororuthenium(II)) and ammonium persulfate, which cross-link aromatic side chains of proteins [165] .
A second route for obtaining stable standards is to use bioconjugated nanoparticles [159, 166] . In this method, nanoparticles with a narrow size range are synthesized as core material, which determines the final size of the oligomer (Fig. 4) . Suitable core materials are silica nanoparticles (SiNaPs), which can easily be adjusted in diameter by the composition of the reactants [167, 168] . The surface of such nanoparticles is then further modified to obtain a functional group that is suitable for a covalent link to a protein monomer. Primary modifications to SiNaPs are introduced by silanization, e.g. with (3-aminopropyl) triethoxysilane, and further modified by e.g. succinic anhydride to introduce carboxylic groups to the surface. Such carboxylic groups can be converted to active esters (NHydroxysuccinimide) that form amide bonds with the lysine side chains or the N terminus of a protein under physiological conditions. However, the formation of such active esters involves catalysts, such as carbodiimides, that activate any carboxylic group and would cross-link protein monomers, too. Therefore, the catalysts have to be removed before the particles are introduced to the protein monomers. The limitations of the method are caused by the positions of primary amine groups in the protein monomer which are bound to the particle surface. Ideally, the amines lie within the aggregation region of the protein, which is the case for Ab and a-synuclein [159, 166] . In such cases, the aggregation of the protein monomers on the particle surface is hampered. Another limitation is the choice of antibodies, as targeting sequences on the antigen may contain lysine, and may be blocked on the standard. Advantages of SiNaP standards are that the diameter is independent of the protein aggregation conditions and the measurable number of accessible peptides on the surface can be directly determined by biochemical assays, such as bicinchoninic acid assay [159] .
Conclusions and perspectives
Recent methodological progress confirms the heterogeneous and polymorphic structural organization of amyloid fibrils and oligomeric aggregates. Mounting evidence suggests that soluble, oligomeric Ab assemblies are the major toxic agents in AD and, thus, maybe the most promising target in drug development. However, development and application of treatments for AD depend on a reliable and early diagnosis. Beside Ab tracers for PET several approaches point to potential biochemical biomarkers in body fluids of which again Ab oligomers are potentially the most direct biomarker for AD.
As an oligomer-specific quantitation platform technology, the sFIDA assay combines an ELISA-like biochemical setup with high-resolution fluorescence microscopy to achieve the essential sensitivity and specificity for the quantitation of low-abundance Ab oligomers in CSF or blood. As a calibration standard bioconjugated silica nanoparticles provide interassay comparability and translation from pixel count to molar Ab oligomer concentration. The automation of the sFIDA assay results in improved intra-assay precision, linearity and sensitivity in comparison to the manual application, and achieves a limit of detection in the subfemtomolar range [157] .
The generic sFIDA principle is not limited to the quantitation of Ab oligomers in the context of AD. H€ ubinger et al. (2012) demonstrated that sFIDA is able to differentiate between a-synuclein fibrils and the soluble form, even when measuring a 100-fold higher monomer concentration. The authors provided the proof of principle that sFIDA is suitable for PD diagnosis based on the aggregated state of a-synuclein as a potential biomarker [169] . Furthermore, Herrmann et al. (2017) presented a-synuclein-coated silica nanoparticles as standard molecules that closely mimic the native oligomers for assay calibration and assessment of interassay variation [166] .
Besides its technological challenges, the relevant regulatory demands for the implementation of a new biomarker assay for medical diagnostics must be considered on its route to market. The transition from research use only (RUO) to in vitro diagnostics (IVD) goes along with specific implications concerning validation, documentation and certifications. For RUOs, no regulatory certifications are required and thus they cannot be used for diagnostic procedures with patients, whereas IVDs require laboratory and assay certification, respectively, such as FDA IVD 510(k) or premarket approval (PMA) in the U.S. through the establishment of appropriate quality systems [170] . In the European Economic Area, in vitro diagnostics are termed as medical devices that are regulated by the in vitro diagnostic medical device directive 98/79/EG which will be replaced by 2022 by the new in vitro diagnostic device regulation (EU) 2017/746. Key requirements focus on traceability, risk-rule-based classification (class A-D) and registration by a notified body as well as conformity and performance assessment by studies on clinical evidence and vigilance throughout the product life cycle including surveillance before and after market placement. In general, these points are commonly addressed by the establishment of an ISO 13485 framework, which comprises the establishment of a quality management system and fulfilment of requirements for respective regulatory purposes, where the respective organization maintains one or more medical device files to demonstrate conformity to requirements and compliance with applicable regulatory demands as well as manages nonconformity detected before and after delivery.
